Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Beta-2-microglobulin in bronchogenic carcinoma].

P Zatloukal1, V Dudková, O Mĕricka

  • 1I. klinika tuberkulózy a respiracních nemocí 1. lékarské fakulty Univerzity Karlovy, Praha.

Sbornik Lekarsky
|November 1, 1990
PubMed
Summary

Serum beta-2-microglobulin levels do not help differentiate bronchogenic carcinoma from other lung diseases. This biomarker showed no significant differences across various lung cancer types or in comparison to non-tumorous conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The TULUNG clinical registry].

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2012
Same author

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same author

[TARCEVA Clinical Registry].

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2010
Same author

A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

[Analysis of symptoms and case history data in the set of 353 patients with lung cancer].

Casopis lekaru ceskych·2009

Area of Science:

  • Oncology
  • Biochemistry
  • Pulmonology

Context:

  • Bronchogenic carcinoma diagnosis often relies on complex methods.
  • Biomarkers for early and accurate lung cancer detection are crucial.
  • Beta-2-microglobulin is a protein found on cell surfaces.

Purpose:

  • To evaluate the utility of serum beta-2-microglobulin as a diagnostic marker for bronchogenic carcinoma.
  • To compare beta-2-microglobulin levels in lung cancer patients versus those with non-tumorous lung diseases.
  • To assess if beta-2-microglobulin levels vary significantly among different histological subtypes of lung cancer.

Summary:

  • Serum beta-2-microglobulin concentrations were measured in 77 patients with bronchogenic carcinoma and 46 with non-tumorous lung diseases.
  • No statistically significant differences were found between the cancer and non-cancer groups.
  • Subgroup analysis of lung cancer types (epidermoid, adenocarcinoma, small-cell) also revealed no significant differences in beta-2-microglobulin levels.

Impact:

  • Serum beta-2-microglobulin assessment is not valuable for the differential diagnosis of bronchogenic carcinoma.
  • This finding suggests alternative biomarkers are needed for lung cancer diagnosis.
  • Further research may explore other protein markers or combinations for improved diagnostic accuracy.

Related Experiment Videos